CLS Blue Sky Blog

Fried Frank explains Chancery Court Decision Providing Guidance on Post-Closing Fraud by Buyer of Portfolio Company

In a recent decision relating to the sale of a portfolio company by one private equity firm to another—Prairie Capital v. Double E (Nov. 24, 2015)—the court provided important guidance with respect to a buyer’s ability to make post-closing fraud claims against a portfolio company’s executives and its private equity fund sellers.

Significance of the decision

In Prairie Capital, the buyer had conditioned its offer on the portfolio company’s meeting certain sales targets. The seller allegedly falsified the books and records and lied to the buyer in order to make it appear that the sales targets had been met. Notwithstanding the egregious factual context, at the pleading stage, the court ruled (consistent with its 2006 Abry decision) that, based on the non-reliance provision in the sale agreement, the buyer could bring a fraud claim only to the extent that it was based on a breach of a representation and warranty set forth in the agreement. Although most of the fraud claims made in Prairie Capital were not dismissed, the court’s disposition of each claim was based on a detailed review of the representations in the agreement to determine whether, by their terms and the dates as of which they spoke, they covered the alleged fraudulent conduct.

Prairie Capital

Background. Funds sponsored by private equity sponsor Prairie Capital sold a portfolio company to an acquisition vehicle formed by funds sponsored by another private equity firm. Only the company’s CEO and its CFO (neither of whom were otherwise affiliated with the sponsor) communicated directly with the buyer during the sale process and the representations and warranties set forth in the stock purchase agreement were made by the company. As is customary in dispositions of portfolio companies by sponsors, the principals of the sponsor were extensively involved in the sale process. The sale strategy emphasized a “growth story”; the buyer’s due diligence focused on confirmation of the historical sales numbers; and the buyer expressly conditioned its final offer (and price increase) on the company’s meeting its March sales target numbers. The sales updates delivered to the buyer through mid-March demonstrated numbers far off the target, but, at the end of March, the report showed that the target had just been met. Based on that information and the company’s further assurances, the buyer signed and closed the transaction.

Fraud allegations. The company had disclosed to the buyer that, in the ordinary course, the company booked sales only after an ordered product was invoiced and shipped to the customer. The buyer alleged that, to meet the March sales target, the company had included in its accounts receivable “revenues” from the sale of products that were not yet invoiced or shipped and had not operated in the ordinary course in generating sale orders (calling people back from vacations and making other extraordinary efforts to meet the target numbers). The buyer also alleged that, prior to March, the company had been falsifying records (for example, shipping products to false addresses on the last day of a month) to maintain the appearance of an upward trend in revenues. The buyer sued the funds and the company’s CEO and CFO for fraud and conspiracy to commit fraud (as well as claims for indemnification) with respect to alleged misrepresentations made both in the stock purchase agreement (the “contractual claims”) and outside the agreement (the “extra-contractual claims”).

Court’s holding. At the pleading stage, the court ruled that, because the agreement contained an effective non-reliance provision (i.e., a statement that the buyer had not relied on information provided outside the sale agreement), the buyer was limited to making fraud claims that were based on misrepresentations in the sale agreement—notwithstanding an exclusive remedy provision with a fraud carve-out (i.e., a statement that indemnification would be the exclusive remedy for breaches of representations and warranties other than in the case of fraud). While the court concluded that most of the claims did constitute breaches of the representations in the agreement (and, accordingly, most of the claims were not dismissed), the court dismissed the claim that the audited financial statements were fraudulent, because the representation in the agreement relating to the audited financials statements did not cover the March 2012 or pre-March 2012 periods during which the alleged misconduct occurred. (The unaudited financial statement representation covered the March 2012 period, but not pre-March 2012.)

Key Points

Practice Points for Buyers

Practice Points for Sellers

The preceding post comes to us from Fried Frank, and is based on their Private Equity Briefing dated as of January 4, 2016, available here.

Exit mobile version